Hydra Biosciences
Hydra Biosciences, biopharmaceutical company, Cambridge, Massachusetts, novel drugs important human diseases, major therapeutic areas, pain, cardiovascular disease, transient receptor potential (TRP) ion channels, molecular regeneration..
Launch date
Employees
Market cap
-
Enterprise valuation
AUD65—97m (Dealroom.co estimates Mar 2015.)
Cambridge Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $200k | Seed | |
$9.3m | Series A | ||
$18.9m | Series B | ||
$34.0m | Series C | ||
$22.0m | Series D | ||
$10.5m | Series E | ||
Total Funding | AUD147m |
Related Content
Recent News about Hydra Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.